PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsdiabetic neuropathies
MeSH D003929 - diabetic neuropathies
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D010523:Peripheral nervous system diseases
0 Companies
0 Drugs
Success rate
D048909:Diabetes complications
6 Companies
3 Drugs
$
Success rate
D003929: 
Diabetic neuropathies
64 Companies
7 Drugs
$
Success rate
D017719:Diabetic foot
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDuloxetine Duloxetine  2013-12-11   
Mexiletine Mexiletine  1995-05-16   
Novast LaboratoriesMexiletine Mexiletine  2021-01-25   
MylanDuloxetine Duloxetine Mylan  2015-06-19   
Johnson & JohnsonBecaplermin Regranex  1999-03-29   
Lupin ResearchDuloxetine Duloxetine  2013-12-11   
Boehringer IngelheimDuloxetine Duloxetine Boehringer Ingelheim  2008-10-08   
Mexiletine Mexitil  1985-12-30   
1
2
3
4
5
6
7
>
Clinical Trials
Historical Success Rate
Phase 1
58%
7/12
Phase 2
58%
29/50
Phase 3
44%
23/52
Approved: 8Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Glenmark Pharmaceuticals
Arm1,
Arm2
Mylan
Citalopram,
Ccb
Johnson & Johnson
Becaplermin,
Fulranumab
Boehringer Ingelheim
Duloxetine,
Mexiletine,
Mexiletine hcl,
Mexiletine hydrochloride,
Benzocaine,
Ccb
Merck & Co
Hydroxocobalamin,
Terfenadine,
FILOREXANT,
Ccb,
Pbo,
Sominex
Eli Lilly
Duloxetine,
Benzocaine,
Ruboxistaurin,
Ly333531,
Viaject,
Ccb,
LY3526318,
LY3857210,
LY3556050
1
2
3
4
5
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use